Recently Developed Neuroprotective Therapies for Acute Stroke: A Qualitative Systematic Review of Clinical Trials

CNS Drugs

Volumn 5, Issue 6, 1996, Pages 457-474

  Dorman, Paul J ^a   Counsell, Carl E ^a   Sandercock, Peter A G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; BARBITURIC ACID DERIVATIVE; CALCIUM ANTAGONIST; CITICOLINE; CLOMETHIAZOLE; CORTICOSTEROID; DEXTRORPHAN; ELIPRODIL; FLUNARIZINE; GANGLIOSIDE; GLUTAMATE RECEPTOR ANTAGONIST; GLYCEROL; ISRADIPINE; LUBELUZOLE; MAGNESIUM; MANNITOL; NAFTIDROFURYL; NALMEFENE; NALOXONE; NICARDIPINE; NIMODIPINE; PHENOBARBITAL; PHENYTOIN; PROPENTOFYLLINE; PROPRANOLOL; PROTIRELIN; SODIUM CHANNEL AFFECTING AGENT; TIRILAZAD; UNINDEXED DRUG;

BRAIN ISCHEMIA; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0029891443     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605060-00005     Document Type: Article

References (118)

1. Sandercock PAG, Celani MG, Ricci S. The likely public health impact in Europe of simple treatments for acute ischaemic stroke [abstract]. Cerebrovasc Dis 1992; 2: 236
2. Harris AI. Handicapped and impaired in Great Britain. London: HMSO, 1971
3. Sandercock PAG, Willems H. Medical treatment of acute ischaemic stroke. Lancet 1992; 339: 537-9
4. Counsell C, Sandercock PAG. The management of patients with acute ischaemic stroke. Curr Med Lit Geriatr 1995; 7 (4): 99-110
5. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26: 503-13
6. Fisher M. Medical therapy for ischemic stroke. In: Fisher M, Bogousslavsky J, editors. Current reviews of cerebrovascular disease. Philadelphia: Current Medicine, 1993
7. The Cochrane Database of Systematic Reviews [database on disk and CD-ROM]. The Cochrane Collaboration; Issue 2. Oxford: Update and Software. London: BMJ Publishing Group, 1995
8. The OSTR Collahoralive Group. The Ottawa Stroke Trials Registry Collaborative Group and the Development of the Ottawa Stroke Trials Registry (OSTR). Controlled Clin Trials 1994; 15: 503-11
9. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischaemia: the ischaemic penumbra. Stroke 1981; 12: 723-5
10. Heiss W-D, Graf R. The ischaemic penumbra. Curr Opin Neurol 1994; 7: 11-9
11. Hossman K-A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994; 36: 557-65
12. Mies G, Iijima T, Hossman K-A. Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat. Neuroreport 1993; 4: 709-11
13. Shinohara M, Dollinger B, Brown G, et al. Cerebral glucose utilization: local changes during and after recovery from spreading cortical depression. Science 1979; 203: 188-90
14. Kocher M. Metabolic and haemodynamic activation of post-ischemic rat brain by cortical spreading depression. J Cereb Blood Flow Metab 1990; 10: 564-71
15. Choksey MS, Costa DC, Iannotti F, et al. 99TCm-HMPAO SPECT studies in traumatic intracerebral haematoma. J Neurol Neurosurg Psychiatry 1991; 54: 6-11
16. Nehls DG, Mendelow D, Graham DI, et al. Experimental intracerebral hemorrhage: progression of hemodynamic changes after production of a spontaneous mass lesion. Neurosurgery 1995; 23: 439-44
17. Choi DW. Excitotoxicity. In: Meldrum BS, editor. Excitatory amino acid antagonists. Oxford: Blackwell, 1991: 216-36
18. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischaemic brain damage. Ann Neurol 1986; 19: 105-11
19. Baker AJ, Zornow MH, Scheller MS. Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin and dopamine metabolites after transient global ischaemia in the rabbit brain. J Neurochem 1991; 57: 1370-9
20. Greenamyre JT, Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1944; 44 Suppl. 8: S7-S13
21. MacDermott AB, Mayer ML, Westbrook GL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 1986; 321: 519-22
22. Rothman SM. Excitotoxins: possible mechanisms of action. Ann NY Acad Sci 1992; 648: 132-9
23. Butcher SP, Bullock R, Graham DI, et al. Correlation between amino acid release and neuropathological outcome in rat brain following middle cerebral artery occlusion. Stroke 1990; 21: 1727-33
24. Benveniste H, Drejer J, Schousboe A, et al. Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischaemia monitored by intracerebral microdialysis. J Neurochem 1984; 43: 1369-74
25. Olney JW. Neurotoxicity of excitatory amino acids. In: McGeer EG, et al., editors. Kainic acid as a tool in neurobiology. New York: Raven Press, 1978: 37-70
26. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol 1992; 34; 106-14
27. Albers GW, Goldberg MP, Choi DW. Do NMDA antagonists prevent neuronal injury? Yes. Arch Neurol 1992; 49: 418-20
28. Choi DW. Nitric oxide: foe or friend to the injured brain? Proc Natl Acad Sci USA 1993; 90: 9741-3
29. Faraci FM, Brian JE. Nitric oxide and the cerebral circulation. Stroke 1994; 25: 692-703
30. Harris RJ, Symon L. Extracellular pH, potassium, and calcium activities in progressive ischaemia of rat cortex. J Cereb Blood Flow Metab 1984; 4: 178-86
31. Hossman K-A, Schuier FJ. Experimental brain infarcts in cats. I. Pathophysiological observations. Stroke 1980; 11: 583-92
32. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613-22
33. Siesjo BK. Pathophysiology and treatment of focal cerebral ischaemia. Part II. Mechanisms of damage and treatment. J Neurosurg 1992; 77: 337-54
34. Belch JJF. Free radicals and their scavenging in stroke. Scot Med J 1992; 37(3): 67-8
35. Kogure K, Kato H. Altered gene expression in cerebral ischaemia. Stroke 1993; 24: 2121-7
36. Harlan JM. Neutrophil mediated vascular injury. Acta Med Scand Suppl. 1985; 715: 123-9
37. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: are they relevant to human disease? Stroke 1990; 21: 1-3
38. Wise RJS, Bernardi S, Frackowiak RSJ, et al. Serial observations on the pathophysiology of acute stroke. The transition trom ischaemia to infarction as reflected in regional oxygen extraction. Brain 1983; 106: 197-222
39. Heiss WD, Huber M, Fink GR, et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992; 12: 193-203
40. 15O-labelled compounds: misery perfusion and luxury perfusion. In: Heiss WD, et al., editors. Clinical efficacy of positron emission tomography. Boston/Dortrecht: Martinus Nijhoff Publishing, 1987: 15-23
41. Heiss WD, Fink GR, Huber M, et al. Positron emission tomography imaging and the therapeutic window. Stroke 1993; 24 Suppl.: I-50-3
42. Warach S, Benfield A, Edelman RR. Prolonged evolution of lesion volume in human stroke determined by diffusion-weighted MRI [abstract]. Neurology 1995; 45 Suppl. 4: 287
43. Muir KW, Lees KR, Hamilton SJC, et al.. A randomised, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke [abstract]. Second International Conference on Neuroprotective Therapy: 1994 Jul 31-Aug 3; New York
44. Albers GW, Atkinson R, Kelley R, et al. on behalf of the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke [abstract]. Stroke 1995; 26: 254-8
45. Fisher M, CNS 1102-003 Investigators. Cerestat (CNS 1102) a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study [abstract]. Cerebrovasc Dis 1994; 4: 245
46. Strand T, Wester PO, CVD Group. A double blind randomized pilot trial of magnesium therapy in acute cerebral infarction [abstract]. 7th Nordic Meeting on Cerebrovascular Disease: 1993 Aug 14-17: Jyräskylä, Finland, 1: 37
47. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995; 26: 1183-8
48. Muir KW, Lees KR. Initial experience with remacemide hydrochloride in patients with acute ischaemic stroke [abstract]. Proceedings of the Second International Conference of Neuroprotective Agents; 1994 Jul 31-Aug 3; Lake George (NY)
49. Grotta J, CGS19755 Study Group. Safety and tolerability of the glutamate antagonist CGS19755 in acute stroke patients [abstract]. Stroke 1994; 25 (1): 255
50. Clark WM, Coull BM. Randomised trial of CGS19755, a glutamate antagonist, in acute ischaemic stroke treatment [abstract]. Neurology 1994; 44 Suppl. 2: A270
51. Diener HC, Hacke W, Hennerici M, et al. The effects of lubeluzole in the acute treatment of ischemic stroke: results of a Phase-2 trial [abstract]. Stroke 1995; 26: 185
52. + channels as targets for neuroprotective drugs. Trends Pharmacol Sci 1995; 16: 309-16
53. Leach MJ, Swan JH, Eisenthal D, et al. BW 619C89, a glutamate release inhibitor, protects against focal cerebral ischaemic damage. Stroke 1993; 24: 1063-7
54. Boxer PA, Cordon JJ, Mann ME, et al. Comparison of phenytoin with non competitive NMDA antagonists in a model of focal brain ischemia in rat. Stroke 1990; 21 Suppl. III: 47-51
55. Rataud J, Debarnot F, Mary V, et al. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994; 172: 19-23
56. Otomo E, Araki G, Mori A, et al. Clinical evaluation of GABA in the treatment of cerebrovascular disorders. Multi-center double blind study in comparison with pyrithioxine and placebo. Arzneimittelforschung 1981; 9: 1511-23
57. Cross AJ, Jones JA, Baldwin HA, et al. Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol 1991; 104: 406-11
58. Yatsu FM, Coull BM. Barbiturate therapy in stroke. In: Fisher M, editor. Medical therapy of acute stroke. New York, Basel: Marcel Dekker Inc., 1989: 109-15
59. Miller LP, Hsu C. Therapeutic potential for adenosine receptor activation in ischaemic brain injury. J Neurotrauma 1992; 9 Suppl. 2: S563-77
60. Huber M, Kittner B, Hojer C, et al. Effect of propentofylline on regional cerebral glucose metabolism in acute ischaemic stroke. J Cereb Blood Flow Metab 1993; 13: 526-30
61. Albers GW, Saenz RE, Moses JA, et al. Safety and tolerance of oral dextromethorphan in patients at risk for brain ischaemia. Stroke 1991; 22(8): 1075-7
62. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 1553-8
63. IS1S-4 Collaborative Group. ISIS-4: a randomised trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
64. Limburg M, Hijdra A. Flunarizine in acute ischemic stroke: a pilot study. In: Limburg M, editor. Stroke: aspects of diagnosis and management. Amsterdam: Rodopi, 1992: 81-4
65. Muir KW, Lees K. Intravenous magnesium efficacy in stroke (IMAGES) trial. Annual Meeting of the British Stroke Research Group: 1995 Jan; Leeds
66. De Ryck M. Lubeluzole: preclinical neuroprotective properties in relation to acute treatment of ischemic stroke. Recent advances in the understanding and therapy of ischaemic stroke: 1994 Nov 30-Dec 1; Philadelphia
67. Vaccarino F, Guidotti A, Costa E. Ganglioside inhibition of glutamate-mediated protein kinase C translocation in primary cultures of cerebellar neurons. Proc Natl Acad Sci USA 1987; 84: 8707-11
68. Argentino C, Sacchetti ML, Toni D, et al. GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study - Hemodilution + Drug. Stroke 1989; 20: 1143-9
69. Di Mascio R, Marchioli R, Tognoni G. From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovasculur disorders. Clin Trial Meta-Analysis 1994; 29: 57-79
70. Mohr JP, Orgogozo JM, Hennerici M. et al. Meta-analysis of nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 197-203
71. Limburg M, Hijdra A. Flunarizine in acute ischemic stroke: a pilot study. Eur Neurol 1990; 30: 121-2
72. Prange H, Hartung J, Hertel G, et al. Treatment of acute stroke with flunarizine i.v. The German Flunarizine Study Group [abstract]. International Conference on Stroke: 1991 Geneva, Switzerland, 39
73. Oczkowski WJ, Hachinski VC, Bogousslavsky J, et al. A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke 1989; 20: 604-8
74. Azcona A, Lataste X. Isradipine in patients with acute ischaemic cerebral infarction: an overview of ASCLEPIOS programme. Drugs 1990; 40 Suppl. 2: 52-7
75. Bridgers SL, Koch G, Munera C, et al. Intravenous nimodipine in acute stroke: interim analysis of randomized trials [abstract]. Stroke 1991; 22: 153
76. Wahlgren NG, MacMahon DG, de Keyser J, et al. and the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994; 4: 204-10
77. Norris JW, LeBrun LH, Anderson BA, Canwin Study Group. Intravenous nimodipine in acute ischaemic stroke. Cerebrovasc Dis 1994; 4: 194-6
78. Heiss WD, Holthoff V, Pawlik G, et al. Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emmision tomography. J Cereb Blood Flow Metab 1990; 10: 127-32
79. Counsell CE, Clarke MJ, Slattery J, et al. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? BMJ 1994; 309: 1677-81
80. Limburg M, Horn J, Vermenten M. Very early nimodipine use in stroke (VENUS). Stoke 1996; 27: 361
81. Sharif NA. Diverse role of thyrotrophin-releasing hormone in brain, pituitary and spinal function. Trends Pharmacol Sci 1985; 6: 119-22
82. Montanari G, Fraioli P, Montemurro L, et al. Comparative study of protirelin tartrate and standard therapy in the treatment of stroke patients. Curr Therap Res 1994; 55: 1211-22
83. Admani AK. New approach to treatment of recent stroke. BMJ 1978; 2: 1678-9
84. Gray CS, French JM, Venables GS, et al. A randomised double-blind controlled trial of naftidrofuryl in acute stroke. Age Ageing 1990; 19: 356-63
85. Steiner TJ, Clifford Rose F. Randomized double-blind placebo-controlled clinical trial of naftidrofuryl in hemiparetic CT-proven acute cerebral hemisphere infarction. In: Clifford Rose F, editor. Stroke: epidemiological, therapeutic and socioeconomic aspects. Royal Society of Medicine Services International Congress and Symposium Series No.99. London: Royal Society of Medicine Services Limited, 1986: 85-98
86. Steiner TJ. Praxilene in stroke treatment in Northern Europe (PRISTINE) [abstract]. Stroke 1994; 25: 544
87. Ohtomo E, Nakajima K, Araki G, et al. Clinical evaluation of LS-121 injection in the treatment of cerebral infarction and cerebral haemorrhage in acute and subacute stages - multi center double-blind study with placebo as the control drug. Clin Eval 1987; 15: 107-42
88. Steiner TJ, MacWalter R, Sanders E for the PRISTINE Group. Naftidrofuryl promote earlier recovery from acute cerebral infarction: principal results of the PRISTINE study [abstract]. Eur J Neurology 1995; 2: 122-3
89. Orgogozo JM, Lebert P, Mosnier M. Double-blind study of naftidrofuryl on secondary outcome after MCA infarction [abstract]. Cerebrovasc Dis 1995; 5: 235
90. Qizilbash N, Murphy M. Meta-analysis of trials of corticosteroids in acute stroke [abstract]. Age Ageing 1993; 22 Suppl. 2: 4
91. Santambrogio S, Martinotti R, Sardella F, et al. Is there a real treatment for stroke? Clinical and statistical comparison of different treatments in 300 patients. Stroke 1978; 9: 130-2
92. Rogvi-Hansen B, Boysen G. I.V. glycerol treatment in acute ischaemic stroke. In: Warlow C, Sandercock P, von Gign J. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing, 1995
93. Qizilbash N, Murphy M. Meta-analysis of trials of glycerol in acute stroke [abstract)]. Age Ageing 1993; 22 Suppl. 2: 4
94. De Reuck J, Decoo D, Vanderdonckt P, et al. A double blind study of neurotropin in patients with acute ischaemic stroke. Acta Neurol Scand 1994; 89: 329-35
95. Zhang RL, Chopp M, Jiang M, et al. Anti-intracellular adhesion molecule-1 antibody reduces ischaemic cell damage after transient hut not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995; 26: 1438-43
96. Sherman DG, Polmar SH. Development of ICAM-1 for stroke: Enlimomab (a murine anti-ICAM-1 antibody) vs placebo in a double-blind randomised trial for ischaemic stroke treated within 6 hours of onset. Recent Advances in the Understanding and Therapy of Ischemic Stroke: 1994 New 30-Dec 1; Philadelphia
97. Smith DH, Gennarelli TA, McIntosh TK. The potential of 21-aminosteroids as neuroprotective therapies in CNS injury. CNS Drugs 1995; 3: 159-64
98. The STIPAS Investigators. Safely study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994; 25: 418-23
99. Peters GR, Hwang L-J, Musch B, et al. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in patients with acute ischaemic stroke (TESS study) [abstract]. Stroke 1996; 27 (1): 32
100. The RANTASS Investigators. Randomized trial of tirilazad in stroke (RANTASS) [abstract]. Stroke 1996; 27 (1): 32
101. Nilsson B. CDP-choline: a short review. In: Tognoni G, Garattini S, editors. Drug treatment and prevention in cerebrovascular disorders. Amsterdam: Elsevier, 1979: 273-7
102. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988; 19: 211-6
103. Guillen F, Buendia C, Herrera J. CDP-Choline in the treatment of acute ischaemic stroke [abstract]. J Neurol 1995; 242 Suppl. 2: S76
104. Sandage BW, Interneuron Pharmaceuticals. I. Citicoline: to promote stroke recovery [abstract]. Recent Advances in the Understanding and Therapy of Ischemic Stroke: 1994 Nov 3-Dec 1; Philadelphia
105. Barer DH, Cruickshank JM, Ebrahim SB, et al. Low dose beta blockade in acute stroke ('BEST' trial): an evaluation. BMJ 1988; 296: 737-41
106. Perraro F, Tosolini G, Pertoldi F, et al. Double-blind placebo-controlled trial of naloxone on motor deficits in acute cerebrovascular disease [letter]. Lancet 1984; 1: 915
107. Fallis RJ, Fisher M, Lobo RA. A double blind trial of naloxone in the treatment of acute stroke. Stroke 1984; 15: 627-9
108. Czlonkowska A, Mendel T, Baranska-Gieruszcvak M. A double-blind controlled trial of naloxone in early treatment of acute stroke. Cerebrovasc Dis 1992; 2: 40-3
109. Federico F, Lucivero V, Lamberti P, et al. A double blind randomised pilot trial of naloxone in the treatment of acute ischemic stroke. Ital J Neurol Sci 1991; 12: 557-63
110. Czlonkowska A, Cyrta B. Effect of naloxone on acute stroke. Pharmacopsychiatry 1988; 21: 98-100
111. Faden AL. The role of opiate antagonists in the treatment of stroke. In: Weinstein PR, Faden AL, editors. Protection of the brain from ischaemia. Baltimore: Williams and Williams, 1990: 265-71
112. Clark WM, Coull B. Randomized trial of cervene, a kappa receptor selective opioid antagonist, in acute ischemic stroke [abstract]. Neurology 1995; 45 Suppl. 4: A241
113. Dick E, Jost BC, Wilp R. Stroke: focus on opportunity. St Louis: Medstrategy Inc., 1994
114. Maccecchini M-L. Partial agonism and neuroprotection [abstract]. Recent advances in the understanding and therapy of ischaemic stroke: 1994 Nov 30- Dec 1; Philadelphia
115. Whitehouse MG. Glycine antagonists - developmental issues for use as neuroprotectants [abstract]. Recent advances in the understanding and therapy of ischaemic stroke: 1994 Nov 30-Dec 1; Philadelphia
116. Lees GJ. Therapeutic potential of AMPA receptor ligands in neurological disorders. CNS Drugs 1996; 5: 51-74
117. Patel TR. Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease. CNS Drugs 1996; 5: 293-310
118. Busto R, Dietrich W, Globus MY, et al. Small differences in intraischemic brain temperature critically determines the extent of neuronal injury. J Cereb Blood Flow Metab 1987; 7: 729-38